State Dependent Dissociation of HERG Channel Inhibitors

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2007 Jun 27

PMID 17592502

Citations 43

Authors

D Stork

E N Timin

S Berjukow

C Huber

A Hohaus

M Auer

S Hering

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Inhibition of HERG channels prolongs the ventricular action potential and the QT interval with the risk of torsade de pointes arrhythmias and sudden cardiac death. Many drugs induce greater inhibition of HERG channels when the cell membrane is depolarized frequently. The dependence of inhibition on the pulsing rate may yield different IC(50) values at different frequencies and thus affect the quantification of HERG channel block. We systematically compared the kinetics of HERG channel inhibition and recovery from block by 8 blockers at different frequencies.

Experimental Approach: HERG channels were expressed heterologously in Xenopus oocytes and currents were measured with the two-electrode voltage clamp technique.

Key Results: Frequency-dependent block was observed for amiodarone, cisapride, droperidol and haloperidol (group 1) whereas bepridil, domperidone, E-4031 and terfenadine (group 2) induced similar pulse-dependent block at all frequencies. With the group 1 compounds, HERG channels recovered from block in the presence of drug (recovery being voltage-dependent). No substantial recovery from block was observed with the second group of compounds. Washing out of bepridil, domperidone, E-4031 and terfenadine was substantially augmented by frequent pulsing. Mutation D540K in the HERG channel (which exhibits reopening at negative voltages) facilitated recovery from block by these compounds at -140 mV.

Conclusion And Implications: Drug molecules dissociate at different rates from open and closed HERG channels ('use-dependent' dissociation). Our data suggest that apparently 'trapped' drugs (group 2) dissociated from the open channel state whereas group 1 compounds dissociated from open and resting states.

Citing Articles

Optimizing experimental designs for model selection of ion channel drug-binding mechanisms.

Patten-Elliott F, Lei C, Preston S, Wilkinson R, Mirams G Philos Trans A Math Phys Eng Sci. 2025; 383(2292):20240227.

PMID: 40078143 PMC: 11904620. DOI: 10.1098/rsta.2024.0227.

Harnessing AlphaFold to reveal hERG channel conformational state secrets.

Ngo K, Yang P, Yarov-Yarovoy V, Clancy C, Vorobyov I bioRxiv. 2024; .

PMID: 38352360 PMC: 10862728. DOI: 10.1101/2024.01.27.577468.

Structural modeling of hERG channel-drug interactions using Rosetta.

Emigh Cortez A, DeMarco K, Furutani K, Bekker S, Sack J, Wulff H Front Pharmacol. 2023; 14:1244166.

PMID: 38035013 PMC: 10682396. DOI: 10.3389/fphar.2023.1244166.

Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685.

Qunies A, Spitznagel B, Du Y, Weaver C, Emmitte K Bioorg Med Chem. 2023; 95:117487.

PMID: 37812884 PMC: 10842602. DOI: 10.1016/j.bmc.2023.117487.

Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment.

Farm H, Clerx M, Cooper F, Polonchuk L, Wang K, Gavaghan D Front Pharmacol. 2023; 14:1110555.

PMID: 37021055 PMC: 10067903. DOI: 10.3389/fphar.2023.1110555.

References

Mitcheson J, Chen J, Lin M, Culberson C, Sanguinetti M . A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000; 97(22):12329-33. PMC: 17341. DOI: 10.1073/pnas.210244497. View

Jo S, Youm J, Lee C, Earm Y, Ho W . Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol. 2000; 129(7):1474-80. PMC: 1571977. DOI: 10.1038/sj.bjp.0703222. View

Vandenberg J, Walker B, Campbell T . HERG K+ channels: friend and foe. Trends Pharmacol Sci. 2001; 22(5):240-6. DOI: 10.1016/s0165-6147(00)01662-x. View

Tseng G . I(Kr): the hERG channel. J Mol Cell Cardiol. 2001; 33(5):835-49. DOI: 10.1006/jmcc.2000.1317. View

Ishii K, Nagai M, Takahashi M, Endoh M . Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovasc Res. 2003; 57(3):651-9. DOI: 10.1016/s0008-6363(02)00774-5. View

Redfern W, Carlsson L, Davis A, Lynch W, Mackenzie I, Palethorpe S . Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003; 58(1):32-45. DOI: 10.1016/s0008-6363(02)00846-5. View

Pearlstein R, Vaz R, Rampe D . Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem. 2003; 46(11):2017-22. DOI: 10.1021/jm0205651. View

Fermini B, Fossa A . The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003; 2(6):439-47. DOI: 10.1038/nrd1108. View

Tsujimae K, Suzuki S, Yamada M, Kurachi Y . Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur J Pharmacol. 2004; 493(1-3):29-40. DOI: 10.1016/j.ejphar.2004.04.015. View

10.

Kirsch G, Trepakova E, Brimecombe J, Sidach S, Erickson H, Kochan M . Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods. 2004; 50(2):93-101. DOI: 10.1016/j.vascn.2004.06.003. View

11.

Witchel H, Dempsey C, Sessions R, Perry M, Milnes J, Hancox J . The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping. Mol Pharmacol. 2004; 66(5):1201-12. DOI: 10.1124/mol.104.001743. View

12.

ARMSTRONG C . Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol. 1971; 58(4):413-37. PMC: 2226036. DOI: 10.1085/jgp.58.4.413. View

13.

Carmeliet E . Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992; 262(2):809-17. View

14.

Curran M, Splawski I, Timothy K, Vincent G, Green E, Keating M . A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80(5):795-803. DOI: 10.1016/0092-8674(95)90358-5. View

15.

Sanguinetti M, Jiang C, Curran M, Keating M . A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995; 81(2):299-307. DOI: 10.1016/0092-8674(95)90340-2. View

16.

Trudeau M, Warmke J, Ganetzky B, Robertson G . HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995; 269(5220):92-5. DOI: 10.1126/science.7604285. View

17.

Grabner M, Wang Z, Hering S, Striessnig J, Glossmann H . Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. Neuron. 1996; 16(1):207-18. DOI: 10.1016/s0896-6273(00)80037-9. View

18.

Suessbrich H, Waldegger S, Lang F, Busch A . Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 1996; 385(1-2):77-80. DOI: 10.1016/0014-5793(96)00355-9. View

19.

Suessbrich H, Schonherr R, Heinemann S, Attali B, Lang F, Busch A . The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997; 120(5):968-74. PMC: 1564549. DOI: 10.1038/sj.bjp.0700989. View

20.

Kiehn J, Thomas D, Karle C, Schols W, Kubler W . Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999; 359(3):212-9. DOI: 10.1007/pl00005344. View